<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2162">
  <stage>Registered</stage>
  <submitdate>30/10/2008</submitdate>
  <approvaldate>30/10/2008</approvaldate>
  <nctid>NCT00784303</nctid>
  <trial_identification>
    <studytitle>Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology</studytitle>
    <scientifictitle>Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E7080-G000-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thyroid Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Thyroid</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - E7080

Experimental: 1 - 


Treatment: drugs: E7080
E7080 given orally continuously at 24 mg, once a day.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the effect of E7080 on the objective tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST).</outcome>
      <timepoint>Months 2, 4, 6, 8 and every two months thereafter.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events, laboratory assessments, and electrocardiograms (ECGs).</outcome>
      <timepoint>AEs reported during all cycles; labs at each week in Cycle 1 and Day 1 at other cycles; ECGs at Day 1 of each cycle</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival, duration of response, and time to response.</outcome>
      <timepoint>At 12 weeks and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival.</outcome>
      <timepoint>At 6 and 12 months, every 3 months in 1st 2 years off study, every 6 months in Years 3 &amp; 4, and yearly thereafter</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile.</outcome>
      <timepoint>Days 1 and 8 of Cycle 1 and Day 1 of other cycles</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Patients must have histologically or cytologically confirmed diagnosis of Medullary
             Thyroid Cancer (MTC) or Differentiated Thyroid Cancer (DTC).

          2. Measurable disease meeting the following criterion:

               1. At least one lesion (= 1.5 cm in longest diameter for non-lymph nodes and =2.0 cm
                  in longest diameter for lymph nodes) which is serially and accurately measurable
                  according to Modified Response Evaluation Criteria in Solid Tumors (RECIST) using
                  either computed tomography (CT) or magnetic resonance imaging (MRI)

               2. Lesions that have had electron beam radiotherapy must show evidence of
                  progressive disease based on Modified Response Evaluation Criteria in Solid
                  Tumors (RECIST) to be deemed a target lesion

          3. Patients must show evidence of disease progression by Response Evaluation Criteria in
             Solid Tumors (RECIST) using site assessment of computed tomography/magnetic resonance
             imaging (CT/MRI) scans within 12 months (+1 month to allow for variances in patient
             scanning intervals) prior to study entry.

          4. Patients with Differentiated Thyroid Cancer (DTC) must be 131-I refractory/resistant:
             never demonstrated 131-I uptake, progression despite 131-I uptake, or cumulative dose
             of 131-I of &gt; 600 mCi (last dose given at least 6 months prior to study entry).

          5. Well controlled blood pressure prior to study entry.

          6. Signed informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Anaplastic thyroid carcinoma, thyroid lymphoma, mesenchymal tumors of the thyroid,
             metastases to the thyroid.

          2. Brain or leptomeningeal metastases.

          3. Significant cardiovascular impairment (history of congestive heart failure &gt; New York
             Heart Association [NYHA] Class II, unstable angina or myocardial infarction within 6
             months of study start, or serious cardiac arrhythmia).

          4. Marked baseline prolongation of QT/QTc interval.

          5. Proteinuria &gt; 1+ or &gt; 30 mg in dipstick testing.

          6. Active hemoptysis (bright red blood of at least Â½ teaspoon) in the 28 days prior to
             study entry.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>116</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Brisbane</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - St Leonards, NSW</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - St Leonards, NSW</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle/Saale</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ferrara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Naples</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gliwice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eisai Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and efficacy of oral E7080 in medullary
      and iodine-131 refractory, unresectable differentiated thyroid cancers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00784303</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>